277 related articles for article (PubMed ID: 22751118)
1. ENTPD1/CD39 is a promising therapeutic target in oncology.
Bastid J; Cottalorda-Regairaz A; Alberici G; Bonnefoy N; Eliaou JF; Bensussan A
Oncogene; 2013 Apr; 32(14):1743-51. PubMed ID: 22751118
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
3. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.
Sun X; Wu Y; Gao W; Enjyoji K; Csizmadia E; Müller CE; Murakami T; Robson SC
Gastroenterology; 2010 Sep; 139(3):1030-40. PubMed ID: 20546740
[TBL] [Abstract][Full Text] [Related]
4. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
[TBL] [Abstract][Full Text] [Related]
5. Targeting adenosine and regulatory T cells in cancer immunotherapy.
Churov A; Zhulai G
Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
[TBL] [Abstract][Full Text] [Related]
6. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia.
Perry C; Hazan-Halevy I; Kay S; Cipok M; Grisaru D; Deutsch V; Polliack A; Naparstek E; Herishanu Y
Ann Hematol; 2012 Aug; 91(8):1271-9. PubMed ID: 22349724
[TBL] [Abstract][Full Text] [Related]
7. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells in transplantation: does extracellular adenosine triphosphate metabolism through CD39 play a crucial role?
Salcido-Ochoa F; Tsang J; Tam P; Falk K; Rotzschke O
Transplant Rev (Orlando); 2010 Apr; 24(2):52-66. PubMed ID: 20153159
[TBL] [Abstract][Full Text] [Related]
9. The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation.
Rissiek A; Baumann I; Cuapio A; Mautner A; Kolster M; Arck PC; Dodge-Khatami A; Mittrücker HW; Koch-Nolte F; Haag F; Tolosa E
J Autoimmun; 2015 Apr; 58():12-20. PubMed ID: 25640206
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.
Muls NG; Dang HA; Sindic CJ; van Pesch V
Mult Scler; 2015 Oct; 21(12):1533-45. PubMed ID: 25662347
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
12. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
[TBL] [Abstract][Full Text] [Related]
13. Target tissue ectoenzyme CD39/CD73-expressing Foxp3+ regulatory T cells in patients with psoriasis.
Zhang HY; Yan KX; Huang Q; Ma Y; Fang X; Han L
Clin Exp Dermatol; 2015 Mar; 40(2):182-91. PubMed ID: 25284153
[TBL] [Abstract][Full Text] [Related]
14. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.
Nagate Y; Ezoe S; Fujita J; Okuzaki D; Motooka D; Ishibashi T; Ichii M; Tanimura A; Kurashige M; Morii E; Fukushima T; Suehiro Y; Yokota T; Shibayama H; Oritani K; Kanakura Y
Leukemia; 2021 Jan; 35(1):107-118. PubMed ID: 32203145
[TBL] [Abstract][Full Text] [Related]
15. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes.
Parodi A; Battaglia F; Kalli F; Ferrera F; Conteduca G; Tardito S; Stringara S; Ivaldi F; Negrini S; Borgonovo G; Simonato A; Traverso P; Carmignani G; Fenoglio D; Filaci G
Cancer Immunol Immunother; 2013 May; 62(5):851-62. PubMed ID: 23359087
[TBL] [Abstract][Full Text] [Related]
16. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.
Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK
FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482
[TBL] [Abstract][Full Text] [Related]
17. CD39 Regulation and Functions in T Cells.
Timperi E; Barnaba V
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360833
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism.
Sundström P; Stenstad H; Langenes V; Ahlmanner F; Theander L; Ndah TG; Fredin K; Börjesson L; Gustavsson B; Bastid J; Quiding-Järbrink M
Cancer Immunol Res; 2016 Mar; 4(3):183-93. PubMed ID: 26787824
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.
Marcus AJ; Broekman MJ; Drosopoulos JH; Pinsky DJ; Islam N; Maliszewsk CR
Ital Heart J; 2001 Nov; 2(11):824-30. PubMed ID: 11770867
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation.
Sattler C; Steinsdoerfer M; Offers M; Fischer E; Schierl R; Heseler K; Däubener W; Seissler J
Cell Transplant; 2011; 20(8):1221-30. PubMed ID: 21176405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
